Disulfidptosis: a new target for metabolic cancer therapy

Altered metabolism is a hallmark of cancer and presents a vulnerability that can be exploited in cancer treatment. Regulated cell death (RCD) plays a crucial role in cancer metabolic therapy. A recent study has identified a new metabolic-related RCD known as disulfidptosis. Preclinical findings sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Peijie, Zhou, Chuntao, Ding, Yuemin, Duan, Shiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134647/
https://www.ncbi.nlm.nih.gov/pubmed/37101248
http://dx.doi.org/10.1186/s13046-023-02675-4
Descripción
Sumario:Altered metabolism is a hallmark of cancer and presents a vulnerability that can be exploited in cancer treatment. Regulated cell death (RCD) plays a crucial role in cancer metabolic therapy. A recent study has identified a new metabolic-related RCD known as disulfidptosis. Preclinical findings suggest that metabolic therapy using glucose transporter (GLUT) inhibitors can trigger disulfidptosis and inhibit cancer growth. In this review, we summarize the specific mechanisms underlying disulfidptosis and outline potential future research directions. We also discuss the challenges that may arise in the clinical translation of disulfidptosis research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02675-4.

Ejemplares similares